

# Emilie Lanoy

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4688754/emilie-lanoy-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

67  
papers

4,586  
citations

32  
h-index

67  
g-index

69  
ext. papers

5,456  
ext. citations

4.8  
avg, IF

5.06  
L-index

#	Paper	IF	Citations
67	Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry. <i>Gynecologic Oncology</i> , <b>2021</b> , 160, 77-82	4.9	0
66	Intratumoral Immunotherapy: From Trial Design to Clinical Practice. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 665-679	12.9	19
65	Trend of antibiotic consumption and its association with influenza-like illnesses in France between 2004 and 2018. <i>European Journal of Public Health</i> , <b>2021</b> , 31, 1137-1143	2.1	2
64	Integrating expert knowledge constraint of time dependent exposures in structure learning for Bayesian networks. <i>Artificial Intelligence in Medicine</i> , <b>2020</b> , 107, 101874	7.4	3
63	No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer. <i>BMC Cancer</i> , <b>2019</b> , 19, 847	4.8	4
62	One or Two Immune Checkpoint Inhibitors?. <i>Cancer Cell</i> , <b>2019</b> , 36, 579-581	24.3	8
61	Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 946-956	12.9	67
60	Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases. <i>Melanoma Research</i> , <b>2018</b> , 28, 111-119	3.3	39
59	Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. <i>European Journal of Cancer</i> , <b>2018</b> , 91, 21-29	7.5	158
58	Estimating causal effects of time-dependent exposures on a binary endpoint in a high-dimensional setting. <i>BMC Medical Research Methodology</i> , <b>2018</b> , 18, 67	4.7	0
57	What's next in using CT scans to better understand cachexia?. <i>Current Opinion in Supportive and Palliative Care</i> , <b>2018</b> , 12, 427-433	2.6	4
56	Statistical approaches for evaluating body composition markers in clinical cancer research. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 311-318	3.5	7
55	Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 3365-3373	3.9	11
54	Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1368-1379	10.3	551
53	In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?. <i>European Journal of Cancer</i> , <b>2017</b> , 87, 65-74	7.5	14
52	Patient-reported tolerability of adverse events in phase 1 trials. <i>ESMO Open</i> , <b>2017</b> , 2, e000148	6	11
51	A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. <i>Cancer Research</i> , <b>2017</b> , 77, 557-565	10.1	5

50	A dose escalation phase 1 study of radiotherapy (RT) in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody ipilimumab in patients (pts) with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9549-9549	2.2	1
49	Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3. <i>Oncotarget</i> , <b>2017</b> , 8, 108786-108801	3.3	18
48	Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. <i>JAMA Dermatology</i> , <b>2016</b> , 152, 45-51	5.1	414
47	Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 3891-3898	3.1	45
46	Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , <b>2016</b> , 10, 395-401	1.5	184
45	Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study. <i>Clinical Drug Investigation</i> , <b>2016</b> , 36, 235-42	3.2	1
44	Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. <i>Annals of Oncology</i> , <b>2016</b> , 27, 214-24	10.3	67
43	Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients. <i>Oncotarget</i> , <b>2016</b> , 7, 25549-57	3.3	12
42	A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials. <i>PLoS ONE</i> , <b>2016</b> , 11, e0154895	3.7	6
41	Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 875-80	7.5	4
40	Impact of dermatologic adverse events induced by targeted therapies on quality of life. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 101, 158-68	7	9
39	Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials. <i>International Journal of Cardiology</i> , <b>2016</b> , 214, 364-9	3.2	
38	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nature Reviews Clinical Oncology</i> , <b>2016</b> , 13, 473-86	19.4	591
37	Uncovering Professional Attitudes Toward Treatment of Rare Carcinomas of the Breast: An International Practice e-Survey Involving 32 Countries. <i>Breast Journal</i> , <b>2016</b> , 22, 96-100	1.2	
36	Nail toxicities induced by systemic anticancer treatments. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, e181-9	21.7	109
35	A randomized, open label, multicenter comparative phase II trial of ipilimumab after isolated limb perfusion (ILP), versus ILP alone in patients with in-transit metastases melanoma stage IIIB and IIIC.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e20107-e20107	2.2	
34	Profiles of screen-failures in phase 1 clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e17518-e17518	2.2	
33	Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. <i>Neurology</i> , <b>2014</b> , 83, 134-41	6.5	85

32	Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2014</b> , 14, 279-88	3.5	12
31	Statistical methods applied to omics data: predicting response to neoadjuvant therapy in breast cancer. <i>Current Opinion in Oncology</i> , <b>2014</b> , 26, 576-83	4.2	3
30	Weight, skeletal muscle mass, and adipose tissue loss during lung cancer patients treatment. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e20627-e20627	2.2	
29	Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study. <i>BMC Infectious Diseases</i> , <b>2013</b> , 13, 200	4	62
28	Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1697-703	10.3	237
27	Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. <i>Current Opinion in Supportive and Palliative Care</i> , <b>2013</b> , 7, 383-9	2.6	93
26	Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. <i>Cancer</i> , <b>2013</b> , 119, 3377-84	6.4	144
25	Lack of regression of anal squamous intraepithelial lesions despite immune restoration under cART. <i>Aids</i> , <b>2013</b> , 27, 401-6	3.5	17
24	Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. <i>BJU International</i> , <b>2012</b> , 110, 1747-53	5.6	47
23	Breast cancer among HIV infected individuals from the ONCOVIH study, in France: therapeutic implications. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 3335-41	7.5	16
22	Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120). <i>AIDS Research and Human Retroviruses</i> , <b>2012</b> , 28, 972-80	1.6	36
21	High-dose ifosfamide (HDI) in metastatic synovial sarcoma: The Institut Gustave Roussy experience. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 10044-10044	2.2	3
20	Tumor burden as an independent prognostic factor in metastatic renal cell carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 397-397	2.2	9
19	Prognostic role of body composition parameters in renal cell carcinoma (RCC). <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4621-4621	2.2	
18	HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. <i>Blood</i> , <b>2011</b> , 118, 44-9	2.2	56
17	When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. <i>Annals of Internal Medicine</i> , <b>2011</b> , 154, 509-15	8	167
16	The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. <i>International Journal of Cancer</i> , <b>2011</b> , 129, 467-75	7.5	60
15	Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score. <i>Neurology</i> , <b>2011</b> , 76, 644-51	6.5	33

14	Skin cancers associated with autoimmune conditions among elderly adults. <i>British Journal of Cancer</i> , <b>2010</b> , 103, 112-4	8.7	44
13	The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. <i>Aids</i> , <b>2010</b> , 24, 123-37	3.5	270
12	When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. <i>International Journal of Biostatistics</i> , <b>2010</b> , 6, Article 18	1.3	115
11	Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults. <i>International Journal of Cancer</i> , <b>2010</b> , 126, 1724-31	7.5	78
10	Observation plans in longitudinal studies with time-varying treatments. <i>Statistical Methods in Medical Research</i> , <b>2009</b> , 18, 27-52	2.3	61
9	How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortaliti2000 survey and death certificates. <i>HIV Medicine</i> , <b>2009</b> , 10, 236-45	2.7	23
8	Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. <i>Aids</i> , <b>2009</b> , 23, 385-93	3.5	78
7	Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. <i>Aids</i> , <b>2009</b> , 23, 2199-208	3.5	33
6	Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. <i>HIV Medicine</i> , <b>2008</b> , 9, 246-56	2.7	47
5	Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. <i>HIV Medicine</i> , <b>2008</b> , 9, 625-35	2.7	19
4	Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction. <i>Thrombosis and Haemostasis</i> , <b>2007</b> , 98, 420-426	7	32
3	Frequency, determinants and consequences of delayed access to care for HIV infection in France. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 89-96	1.6	82
2	Predictors identified for losses to follow-up among HIV-seropositive patients. <i>Journal of Clinical Epidemiology</i> , <b>2006</b> , 59, 829-835	5.7	77
1	Comparison of dynamic treatment regimes via inverse probability weighting. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2006</b> , 98, 237-42	3.1	168